Tag: Revive Therapeutics - Page 5 - Psychedelic Alpha

Read more about the article Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Post published:September 29, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Post published:September 21, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Post published:September 16, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Post published:September 2, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Post published:August 31, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Post published:August 26, 2020
Post category:Press Release

Read more about the article Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

Post published:August 20, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

Post published:August 14, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

Post published:August 11, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

Post published:August 5, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.